0001415889-24-002282.txt : 20240202
0001415889-24-002282.hdr.sgml : 20240202
20240202160534
ACCESSION NUMBER: 0001415889-24-002282
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240131
FILED AS OF DATE: 20240202
DATE AS OF CHANGE: 20240202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Heerma Peter
CENTRAL INDEX KEY: 0001789617
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36257
FILM NUMBER: 24591354
MAIL ADDRESS:
STREET 1: C/O TRAVERE THERAPEUTICS, INC.
STREET 2: 3611 VALLEY CENTRE DRIVE, SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Travere Therapeutics, Inc.
CENTRAL INDEX KEY: 0001438533
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 262383102
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3611 VALLEY CENTRE DR
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 888-969-7879
MAIL ADDRESS:
STREET 1: 3611 VALLEY CENTRE DR
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: Retrophin, Inc.
DATE OF NAME CHANGE: 20130220
FORMER COMPANY:
FORMER CONFORMED NAME: Desert Gateway, Inc.
DATE OF NAME CHANGE: 20080625
4
1
form4-02022024_040211.xml
X0508
4
2024-01-31
0001438533
Travere Therapeutics, Inc.
TVTX
0001789617
Heerma Peter
C/O TRAVERE THERAPEUTICS, INC.
3611 VALLEY CENTRE DRIVE, SUITE 300
SAN DIEGO
CA
92130
false
true
false
false
CHIEF COMMERCIAL OFFICER
0
Common Stock
2024-01-31
4
A
0
25000
0
A
103698
D
Common Stock
2024-02-01
4
S
0
4195
8.5313
D
99503
D
Employee stock option (right to buy)
8.93
2024-01-31
4
A
0
65000
0
A
2034-01-30
Common Stock
65000
65000
D
Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
The weighted average sale price for the reported transaction was $8.5313, and the range of prices were between $8.5302 and $8.5321. Upon request by the SEC staff, the Issuer or any securityholder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.
/s/ Elizabeth E. Reed, Attorney-in-Fact
2024-02-02